Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

MC2 Therapeutics Ltd.

Home Clinical Trial Sponsors and OrganizationsMC2 Therapeutics Ltd.

MC2 Therapeutics Ltd.

ACTIVE

United Kingdomdrugdeliverysolutions.comSubsidiary

Part of Mc2 Therapeutics AS

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

5

4 active

Approvals

1

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

80.0%

Phase 2

1

20.0%

Trial Status Distribution

Active, not recruiting

4

80.0%

Completed

1

20.0%

Clinical Trials

Trials sponsored by this organization (5)

People suffering from Chronic Kidney Disease-associated Pruritus (CKD aP) are treated with a new cream, MC2 25 Cream, or placebo (same Cream without active ingredient) for 12 weeks to reduce their burden and to prove the new cream is safe when used

May 2022108 participants

Evaluation of the efficacy and safety of a new formulation (Cream) for the treatment of psoriasis vulgaris in adults as compared to a product already availible on the market and placebo.

Active, not recruiting

Nov 2018490 participants

Evaluation of a new formulation (cream) to evaluate the safety in adolescent subjects with extensive psoriasis vulgaris.

Active, not recruiting

May 201830 participants

Evaluation of a new formulation (cream) to evaluate the safety in adolescent subjects with extensive psoriasis vulgaris.

Active, not recruiting

May 201830 participants

Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patients

Active, not recruiting

May 2015264 participants

Approvals

Approvals by Agency

FDA

Food and Drug Administration

1

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials5
Approvals1
News

Back to Organizations